CN105797163A - 一种用于治疗视网膜疾病的药物及其制备方法 - Google Patents
一种用于治疗视网膜疾病的药物及其制备方法 Download PDFInfo
- Publication number
- CN105797163A CN105797163A CN201510258263.7A CN201510258263A CN105797163A CN 105797163 A CN105797163 A CN 105797163A CN 201510258263 A CN201510258263 A CN 201510258263A CN 105797163 A CN105797163 A CN 105797163A
- Authority
- CN
- China
- Prior art keywords
- medicine
- sch442416
- polyamide
- preparation
- retinal diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 30
- 208000017442 Retinal disease Diseases 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 229940079593 drug Drugs 0.000 title description 4
- AEULVFLPCJOBCE-UHFFFAOYSA-N LSM-3027 Chemical compound C1=CC(OC)=CC=C1CCCN1C(N=C(N)N2C3=NC(=N2)C=2OC=CC=2)=C3C=N1 AEULVFLPCJOBCE-UHFFFAOYSA-N 0.000 claims abstract description 31
- 239000003960 organic solvent Substances 0.000 claims abstract description 13
- 239000002105 nanoparticle Substances 0.000 claims abstract description 11
- 239000005557 antagonist Substances 0.000 claims abstract description 9
- 238000004945 emulsification Methods 0.000 claims abstract description 4
- 238000002390 rotary evaporation Methods 0.000 claims abstract description 4
- 238000005303 weighing Methods 0.000 claims abstract description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- 239000000523 sample Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000002604 ultrasonography Methods 0.000 claims description 3
- 238000001704 evaporation Methods 0.000 claims description 2
- 239000000243 solution Substances 0.000 abstract description 12
- 229920000962 poly(amidoamine) Polymers 0.000 abstract description 9
- 239000003889 eye drop Substances 0.000 abstract description 7
- 239000002245 particle Substances 0.000 abstract description 6
- 229940012356 eye drops Drugs 0.000 abstract description 2
- 239000007853 buffer solution Substances 0.000 abstract 2
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 6
- 206010021143 Hypoxia Diseases 0.000 description 5
- 230000002207 retinal effect Effects 0.000 description 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 210000001525 retina Anatomy 0.000 description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 206010020852 Hypertonia Diseases 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000000385 dialysis solution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 102000007471 Adenosine A2A receptor Human genes 0.000 description 1
- 108010085277 Adenosine A2A receptor Proteins 0.000 description 1
- 102000006941 Amino Acid Transport System X-AG Human genes 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 102000012002 Aquaporin 4 Human genes 0.000 description 1
- 108010036280 Aquaporin 4 Proteins 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 108091006151 Glutamate transporters Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010058046 Post procedural complication Diseases 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000004378 blood-retinal barrier Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 201000005667 central retinal vein occlusion Diseases 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002592 gangliocyte Anatomy 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 102000005396 glutamine synthetase Human genes 0.000 description 1
- 108020002326 glutamine synthetase Proteins 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FVLAYJRLBLHIPV-UHFFFAOYSA-N pyrimidin-5-amine Chemical compound NC1=CN=CN=C1 FVLAYJRLBLHIPV-UHFFFAOYSA-N 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 208000032253 retinal ischemia Diseases 0.000 description 1
- 208000004644 retinal vein occlusion Diseases 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明一种用于治疗视网膜疾病的药物，含有A2AR 拮抗剂SCH 442416，在所述的拮抗剂SCH 442416的外部包裹有聚酰胺-胺。本发明还提供了上述的一种用于治疗视网膜疾病的药物的制备方法，先称取SCH442416，将SCH442416溶解于有机溶剂中；再称取聚酰胺-胺，将聚酰胺-胺溶解于缓冲液中；将SCH442416有机溶液加入到聚酰胺-胺的缓冲液中，采用进行超声乳化，再采用旋转蒸发除去有机溶剂制得聚酰胺-胺包裹的SCH442416纳米颗粒。本发明所述的PAMAM纳米包裹SCH 442416滴眼液纳米粒粒径为169.2nm，具有良好的生物相容性，包裹率高，且易分解。
Description
技术领域：
本发明属于生物医药领域，尤其涉及一种滴眼液，具体来说是一种用于治疗视网膜疾病的药物及其制备方法。
背景技术：
在2010年国际防盲协会第八次大会上，已将视网膜疾病作为视力障碍和致盲的主要原因之一。据统计，在全球，糖尿病性视网膜病变、老年黄斑变性、视网膜脱离等视网膜疾病的致盲率约占15-20％。多种视网膜疾病的终点是多种病理状态(视网膜缺血、缺氧、血-视网膜屏障的破坏、高眼压)，视网膜组织水肿，视网膜神经节细胞的损伤、凋亡。
视网膜组织对低氧非常敏感，多种视网膜疾病(青光眼、黄斑变性、视网膜中央静脉阻塞、糖尿病性视网膜病变等)的病程发生发展过程中均有缺血缺氧的表现。研究发现：在病理状态下(低氧，高眼压，炎症等)，视网膜组织内谷氨酸浓度显著增加，产生细胞毒性作用，从而引神经细胞损伤、坏死。而视网膜上的Müller细胞则应急激活，细胞增大伸长，进入视神经纤维层，包裹RGCs胞体；并释放一些神经营养因子，如睫状神经生长因子、血管内皮生长因子等，激活其下游靶点，从而保护视网膜各类细胞免受或减轻损伤。
腺苷A2A受体已被证实能够影响诸如缺氧性、缺血性、感染性以及变态反应性疾病等一系列疾病的发病过程。在中枢神经系统，A2AR高表达于胶质细胞、巨噬细胞及神经元。近几年来，A2AR拮抗剂在CNS疾病(帕金森病、阿尔茨海默病等)中的神经保护作用得到广泛关注。目前研究认为其作用在于：A2AR拮抗剂可抑制胶质细胞对谷氨酸的释放，调整k+的浓度，水的转运的方面从而保护神经元。我们实验也发现A2AR拮抗剂(SCH442416＝＝＝2-(2-以呋喃)-7-【3-(4-甲氧基苯基丙酮)丙基】-7H-吡唑【4,3-e】【1,2,4】三唑【1,5-c】嘧啶-5-胺)可上调Müller细胞上谷氨酰胺合成酶、谷氨酸转运体、水通道蛋白-4、内流性K+通道4.1等蛋白的表达，从而保护视网膜神经节细胞，其结构式如下所示：
目前治疗视网膜疾病采用的治疗手段是：玻璃体切割术，眼底激光光凝术、玻璃体腔注药术。这些治疗手段均存在不同程度的手术风险和术后并发症。因此，我们拟采用眼部滴眼液的方式治疗视网膜疾病。总所周知，眼部滴眼液由于眨眼，眼球运动，角膜的屏障作用，不利于药物进入眼内。
发明内容：
本发明的目的在于提供一种用于治疗视网膜疾病的药物及其制备方法，所述的这种用于治疗视网膜疾病的药物及其制备方法解决了现有技术中的治疗视网膜疾病的眼部滴眼液中的有效成分难以进入眼睛中的有效部位，治疗效果不佳的技术问题。
本发明提供了一种用于治疗视网膜疾病的药物，含有A2AR拮抗剂SCH442416，在所述的拮抗剂SCH442416的外部包裹有聚酰胺-胺。
本发明还提供了上述用于治疗视网膜疾病的药物的制备方法，包括如下步骤：
1)称取SCH442416，将SCH442416溶解于有机溶剂中，在有机溶剂中，所述的SCH442416的浓度为40～60μg/ml；
2)称取聚酰胺-胺，将聚酰胺-胺溶解于缓冲液中；
3)在聚酰胺-胺的缓冲液中加入步骤1)的SCH442416有机溶液，其中，聚酰胺-胺和SCH442416有机溶液的质量体积比为5mg:0.50～1.0ml；
4)将步骤3)获得的溶液采用探头超声仪进行超声乳化；
5)将步骤4)获得的均一稳定的乳剂转入一个容器中，旋转蒸发除去有机溶剂制得聚酰胺-胺包裹的SCH442416纳米颗粒。
进一步的，步骤5)中，采用旋转蒸发仪蒸发除去有机溶剂，参数为：水浴温度28～32℃、真空度0.07～0.08MPa。
进一步的，所述的探头超声仪的超声参数为超声处理5s、停2s、进行40次、功率200W。
进一步的，所述的SCH442416的浓度为50μg/ml。
进一步的，所述的缓冲液为PBS溶液。
进一步的，所述的有机溶剂为二氯甲烷。
进一步的，聚酰胺-胺和SCH442416有机溶液的质量体积比为5mg:0.75ml。
纳米颗粒是直径在1-1000nm间的多聚胶体颗粒，以大分子多聚体为载体，药物可通过溶解、嵌入、包裹或吸附等方式与之结合。纳米载药系统的胶体性质有助于延长药物在眼部的停留时间，具有增加角膜通透性、增加药物眼内吸收、缓释增效的特点。本发明采用的聚酰胺-胺[Poly(amidoamine)PAMAM]是树状大分子，它的特点是：精确的分子结构、分子本身具有纳米尺寸、分子内存在空腔、良好的相容性、低的熔体粘度和溶液粘度。
本发明所述的PAMAM纳米包裹SCH442416滴眼液纳米粒粒径为169.2nm，具有良好的生物相容性，无毒性，并包裹率高，且易分解。本发明的制备方法简单，快速，可望大规模实际应用。
本发明与现有技术相对比，其效果是积极和明显的。本发明使用PAMAM包裹SCH442416制备成滴眼液治疗视网膜疾病，提高了眼部药物的生物利用度，为新的眼部用药研发提供新的思路。
附图说明：
图1是显示了本发明的用于治疗视网膜疾病的药物的粒径分布图。
图2是显示了本发明的用于治疗视网膜疾病的药物的释放图。横坐标为释放时间(min)，纵坐标为释放百分率。
具体实施方式：
实施例1一种用于治疗视网膜疾病的药物的制备方法
(1)称取PAMAM5mg，用2mlPBS溶液(pH7.4)溶解后，加入0.75mLSCH442416二氯甲烷溶液(50μg/ml)；
(2)采用探头超声仪进行超声乳化，超声参数：超5s、停2s、40次、功率200W；
(3)将制得的均一稳定的乳剂转入圆底烧瓶中，旋转蒸发除去有机溶剂制得PAMAM纳米粒，参数：水浴温度30±2℃、真空度0.07～0.08MPa。
实施例2包封率测定
将样品溶液置于透析袋(截留分子量3500)中，100mlPBS溶液(pH7.4)中透析处理5min，测定透析液中药物含量。
透析液中未检测出SCH442416，包封率为100％。
实施例3粒径测定
采用Malvern粒度分析仪测定PAMAM纳米粒的粒径，如图1所示，载药PAMAM纳米粒的粒径为169.2nm。
实施例4释放考察
(1)采用实施例的方法制备PAMAM纳米粒溶液1ml，取0.2ml置于10ml容量瓶中，加甲醇溶解定容；
(2)取0.8ml置于透析袋(截留分子量3500)中，80mlPBS溶液(pH7.4)室温条件下透析考察药物释放，分别于0.25、0.5、0.75、1、1.5、2、2.5、3、3.5、4、5、8、10h取样20μl进行HPLC分析，测定释放百分率。发现10h累积释放55.6％的药物(如图2所示)。
Claims (8)
1.一种用于治疗视网膜疾病的药物，其特征在于：含有A2AR拮抗剂SCH442416，在所述的拮抗剂SCH442416的外部包裹有聚酰胺-胺。
2.一种制备如权利要求1所述的用于治疗视网膜疾病的药物的方法，其特征在于：包括如下步骤：
1）称取SCH442416，将SCH442416溶解于有机溶剂中，在有机溶剂中，所述的SCH442416的浓度为40~60μg/ml；
2）称取聚酰胺-胺，将聚酰胺-胺溶解于缓冲液中；
3）在聚酰胺-胺的缓冲液中加入步骤1）的SCH442416有机溶液，其中，聚酰胺-胺和SCH442416有机溶液的质量体积比为5mg:0.50~1.0ml；
4）将步骤3）获得的溶液采用探头超声仪进行超声乳化；
5）将步骤4）获得的均一稳定的乳剂转入一个容器中，旋转蒸发除去有机溶剂制得聚酰胺-胺包裹的SCH442416纳米颗粒。
3.如权利要求2所述的用于治疗视网膜疾病的药物的制备方法，其特征在于：步骤5）中，采用旋转蒸发仪蒸发除去有机溶剂，参数为：水浴温度28~32℃、真空度0.07~0.08MPa。
4.如权利要求2所述的用于治疗视网膜疾病的药物的制备方法，其特征在于：所述的探头超声仪的超声参数为超声处理5s、停2s、进行40次、功率200W。
5.如权利要求2所述的用于治疗视网膜疾病的药物的制备方法，其特征在于：所述的SCH442416的浓度为50μg/ml。
6.如权利要求2所述的用于治疗视网膜疾病的药物的制备方法，其特征在于：所述的缓冲液为PBS溶液。
7.如权利要求2所述的用于治疗视网膜疾病的药物的制备方法，其特征在于：所述的有机溶剂为二氯甲烷。
8.如权利要求2所述的用于治疗视网膜疾病的药物的制备方法，其特征在于：聚酰胺-胺和SCH442416有机溶液的质量体积比为5mg:0.75ml。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510258263.7A CN105797163B (zh) | 2015-05-20 | 2015-05-20 | 一种用于治疗视网膜疾病的药物及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510258263.7A CN105797163B (zh) | 2015-05-20 | 2015-05-20 | 一种用于治疗视网膜疾病的药物及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105797163A true CN105797163A (zh) | 2016-07-27 |
| CN105797163B CN105797163B (zh) | 2018-07-13 |
Family
ID=56465533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510258263.7A Expired - Fee Related CN105797163B (zh) | 2015-05-20 | 2015-05-20 | 一种用于治疗视网膜疾病的药物及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105797163B (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111093669A (zh) * | 2017-08-14 | 2020-05-01 | 法斯瑞斯公司 | 用于治疗癌症的腺苷受体拮抗剂的微颗粒制剂 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102429870A (zh) * | 2011-12-21 | 2012-05-02 | 中国药科大学 | 一种喜树碱类药物的新型肿瘤靶向树状聚合物纳米载体 |
| US20120134979A1 (en) * | 2010-11-22 | 2012-05-31 | Yang Xia | Methods and compositions for the treatment of sickle cell disease |
| CN103990145A (zh) * | 2014-06-17 | 2014-08-20 | 福州大学 | 具有肿瘤靶向的叶酸-pamam-熊果酸纳米药物及其制备方法 |
-
2015
- 2015-05-20 CN CN201510258263.7A patent/CN105797163B/zh not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120134979A1 (en) * | 2010-11-22 | 2012-05-31 | Yang Xia | Methods and compositions for the treatment of sickle cell disease |
| CN102429870A (zh) * | 2011-12-21 | 2012-05-02 | 中国药科大学 | 一种喜树碱类药物的新型肿瘤靶向树状聚合物纳米载体 |
| CN103990145A (zh) * | 2014-06-17 | 2014-08-20 | 福州大学 | 具有肿瘤靶向的叶酸-pamam-熊果酸纳米药物及其制备方法 |
Non-Patent Citations (5)
| Title |
|---|
| ANDREI A. IVANOV等: "Molecular modeling of a PAMAM-CGS21680 dendrimer bound to an A2A adenosine receptor homodimer", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 * |
| SERGE MIGNANI等: "Advances in Combination Therapies Based on Nanoparticles for Efficacious Cancer Treatment: An Analytical Report", 《BIOMACROMOLECULES》 * |
| T. SANTHOSH KUMAR等: "Molecular probes for the A2A adenosine receptor based on a pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine scaffold", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 * |
| XIAOLI KANG等: "The Effect of A2A Receptor Antagonist (SCH 442416) on the mRNA Expression of Kir 2.1 and Kir 4.1 Channels in Rat Retinal Müller Cells Under Hypoxic Conditions in Vitro", 《ADV CLIN EXP MED》 * |
| 于军等: "腺苷及其衍生物在眼科应用的研究进展", 《中华实验眼科杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111093669A (zh) * | 2017-08-14 | 2020-05-01 | 法斯瑞斯公司 | 用于治疗癌症的腺苷受体拮抗剂的微颗粒制剂 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105797163B (zh) | 2018-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Preparation and evaluation of naringenin-loaded sulfobutylether-β-cyclodextrin/chitosan nanoparticles for ocular drug delivery | |
| Li et al. | A potential new therapeutic system for glaucoma: solid lipid nanoparticles containing methazolamide | |
| Shi et al. | Chitosan grafted methoxy poly (ethylene glycol)-poly (ε-caprolactone) nanosuspension for ocular delivery of hydrophobic diclofenac | |
| Pinkerton et al. | Formation of stable nanocarriers by in situ ion pairing during block-copolymer-directed rapid precipitation | |
| Ibrahim et al. | Pharmaceutical nanotechnology nanoparticle-based topical ophthalmic formulations for sustained celecoxib release | |
| Chellappan et al. | Formulation and characterization of glibenclamide and quercetin-loaded chitosan nanogels targeting skin permeation | |
| Gulati et al. | Intranasal delivery of chitosan nanoparticles for migraine therapy | |
| de Oliveira et al. | Cutting-edge advances in therapy for the posterior segment of the eye: Solid lipid nanoparticles and nanostructured lipid carriers | |
| Hou et al. | Preparation and characterization of novel drug-inserted-montmorillonite chitosan carriers for ocular drug delivery | |
| US20180185275A1 (en) | Membrane-adherent self-assembled systems for treatment of ocular disorders | |
| Jiang et al. | Plga nanoparticle platform for trans-ocular barrier to enhance drug delivery: A comparative study based on the application of oligosaccharides in the outer membrane of carriers | |
| Hou et al. | Preparation and in vitro study of lipid nanoparticles encapsulating drug loaded montmorillonite for ocular delivery | |
| Ibrahim et al. | Natural bioadhesive biodegradable nanoparticles-based topical ophthalmic formulations for sustained celecoxib release: in vitro study | |
| JP7323458B2 (ja) | 目薬送達製剤 | |
| Thakur et al. | Thermosensitive injectable hydrogel containing carboplatin loaded nanoparticles: A dual approach for sustained and localized delivery with improved safety and therapeutic efficacy | |
| Ibrahim et al. | Novel topical ophthalmic formulations for management of glaucoma | |
| BR112019011067A2 (pt) | preparação de complexos sólidos de ciclodextrina para administração de ingredientes farmacêuticos oftalmológicos ativos | |
| Kumar et al. | Itraconazole loaded nano-structured lipid carrier for topical ocular delivery: Optimization and evaluation | |
| JP6832276B2 (ja) | 薬剤の眼内送達 | |
| El-Emam et al. | Formulation and pathohistological study of mizolastine–solid lipid nanoparticles–loaded ocular hydrogels | |
| Mirgorodskaya et al. | Polyelectrolyte nanocontainers: Controlled binding and release of indomethacin | |
| Fayyaz et al. | Dextran-based oxygen nanobubbles for treating inner retinal hypoxia | |
| Desai et al. | In vitro and in vivo evaluation of cyclosporine-graphene oxide laden hydrogel contact lenses | |
| Halasz et al. | Utilization of apatinib-loaded nanoparticles for the treatment of ocular neovascularization | |
| Liu et al. | Wettability and contact angle affect precorneal retention and pharmacodynamic behavior of microspheres |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 200020 Chongqing South Road, Huangpu District, Huangpu District, Shanghai Applicant after: Yu Jun Address before: 200092 the 2 floor of the Department of optometry, Xinhua Hospital, 1669 Yangpu District, Shanghai. Applicant before: Yu Jun |
|
| CB02 | Change of applicant information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180713 |